Otulfi, the fourth Fresenius biosimilar available in the U.S., is available in vial and prefilled syringe presentations. (Photo: Business Wire) The Fresenius ustekinumab biosimilar, Otulfi ® was ...
Julia Anthony from SOLUtion Medical emphasizes usability and patient-centric design for the company’s dual chamber prefilled ...
The new single-dose prefilled syringes will be available in 40 USP units/0.5mL and 80 USP units/mL dosage strengths. The Food and Drug Administration (FDA) has approved Purified Cortrophin ® Gel ...
The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, ...
The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for ...
Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 ...
Most participating nurses (87%) worked in organizations that have been using Carpuject prefilled syringe cartridges for more than 2 years. When preparing a Carpuject syringe, 8% of nurses told us ...
--(BUSINESS WIRE)--Fresenius Kabi, an operating company ... a 45 mg/0.5 mL and 90 mg/mL single-dose prefilled syringe for injection and a 130 mg/26 mL (5 mg/mL) single dose vial for IV infusion.
The new single-dose prefilled syringes will be available in 40 USP units/0.5mL and 80 USP units/mL dosage strengths. The Food and Drug Administration (FDA) has approved Purified Cortrophin ® Gel ...
Fresenius Kabi, an operating company of Fresenius, and Formycon AG, a leading, independent developer of high-quality biosimilars, announced today that the ustekinumab biosimilar Otulfi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback